Teva puts GSK and Amarin on notice with generic Lovaza launch

Lovaza--Courtesy of GlaxoSmithKline

Watch out, GlaxoSmithKline--and Amarin. Teva Pharmaceutical Industries ($TEVA) has launched its generic version of Glaxo's ($GSK) fish-oil pill, Lovaza, designed to lower triglyceride levels in patients with cardiovascular disease. Lovaza delivers $1.1 billion in U.S. sales for Glaxo annually, Teva says. But GSK isn't the only company likely to suffer from Teva's generic. Amarin's ($AMRN) rival product Vascepa will have to face the competition, too. Report

Suggested Articles

First-round winners in the #FierceMadness ad tournament are decided, with the victors advancing to compete in Round 2's field of 32.

Pfizer and Merck KGaA haven’t had much luck with Bavencio in ovarian cancer, so the pair are calling it quits on a late-stage trial.

Merck continues its HPV awareness campaign with a twist. In new TV, a parent is the narrator for the first time in the three-year-old campaign.